Literature DB >> 24099051

Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy.

Ettore Beghi1, Giorgia Giussani, Salvatore Grosso, Alfonso Iudice, Angela La Neve, Francesco Pisani, Luigi M Specchio, Alberto Verrotti, Giuseppe Capovilla, Roberto Michelucci, Gaetano Zaccara.   

Abstract

The Italian League Against Epilepsy has issued evidence-based guidelines to help practicing physicians in their decision to stop or withhold antiepileptic drugs (AEDs) in patients achieving a prolonged period of seizure freedom. Six adult and two child neurologists, divided into four pairs, critically appraised 128 published reports and provided graded recommendations answering 15 key questions: length of the seizure-free period after treatment initiation, difference in seizure-free periods in children and adults, electroencephalography (EEG) pattern at the time of discontinuation, etiology of epilepsy, seizure type(s), patient's age and sex, family history of epilepsy, history of febrile seizures, epilepsy syndrome, seizure frequency before entering remission, duration of active epilepsy, tapering period, number and type of AEDs taken at time of discontinuation, combination of risk factors for recurrence, and length of patient monitoring after treatment discontinuation. Based on the available data, the following recommendations can be outlined: (1) antiepileptic treatment might be discontinued after a minimum period of 2 years of seizure freedom; shorter seizure-free periods are associated to a higher risk of relapse; (2) in children, AED discontinuation could be considered after less than two seizure-free years because of a marginally higher risk of relapse for early withdrawal; (3) factors, such as abnormal EEG (including epileptiform abnormalities) at the time of treatment discontinuation, a documented etiology of seizures (including mental retardation, perinatal insults, and abnormal neurologic examination), partial seizures, or an older age at disease onset, enhance the risk of relapse; however, patients should not be encouraged to withhold treatment unless a combination of two or more of these factors is present; (4) female sex, family history of epilepsy, history of febrile seizures, disease length/severity, and number and type of drugs taken should not influence the decision to stop treatment; (5) epilepsy syndrome should be always included in the decision process; (6) slow (at least 6 months) AED discontinuation should be encouraged; in any case the duration of the tapering period should be tailored to the patient's needs and preference; and (7) patient discontinuing treatment should be followed for no <2 years. As a general habit, the decision to stop treatment should be discussed and shared with each patient, taking into account social and personal complications of a seizure relapse and the medical complications of chronic AED treatment. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Antiepileptic drugs; EEG; Epilepsy; Etiology; Seizure; Seizure freedom; Withdrawal

Mesh:

Substances:

Year:  2013        PMID: 24099051     DOI: 10.1111/epi.12305

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  27 in total

1.  Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents.

Authors:  Joseph T Hanlon; Xinhua Zhao; Jennifer G Naples; Sherrie L Aspinall; Subashan Perera; David A Nace; Nicholas G Castle; Susan L Greenspan; Carolyn T Thorpe
Journal:  J Am Geriatr Soc       Date:  2017-02-02       Impact factor: 5.562

2.  Stay, Hit, or Fold? What Do You Do If the Treatment May Be as Bad as the Problem-Results of a Q-PULSE Survey.

Authors:  Chad Carlson
Journal:  Epilepsy Curr       Date:  2014 Nov-Dec       Impact factor: 7.500

3.  Practice Current: When do you stop antiepileptic drugs in patients with genetic generalized epilepsies and in those with focal epilepsies?

Authors:  Luca Bartolini
Journal:  Neurol Clin Pract       Date:  2016-12

4.  Juvenile myoclonic epilepsy-what does the future look like?

Authors:  Cynthia Harden
Journal:  Epilepsy Curr       Date:  2014-05       Impact factor: 7.500

5.  Relative Seizure Relapse Risks Associated with Antiepileptic Drug Withdrawal After Different Seizure-Free Periods in Adults with Focal Epilepsy: A Prospective, Controlled Follow-Up Study.

Authors:  Xinshi Wang; Ruqian He; Rongyuan Zheng; Siqi Ding; Yi Wang; Xueying Li; Yingjie Hua; Qingyi Zeng; Niange Xia; Zhenguo Zhu; Patrick Kwan; Huiqin Xu
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

6.  Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Giorgia Giussani; Domenico Italiano; Vittoria Cianci; Chiara Sueri; Edoardo Spina; Ettore Beghi; Umberto Aguglia
Journal:  Neurol Sci       Date:  2016-01-25       Impact factor: 3.307

7.  Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.

Authors:  Joseph T Hanlon; Todd P Semla; Kenneth E Schmader
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

Review 8.  Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective.

Authors:  Manuel Toledo; Barbara Mostacci; Magdalena Bosak; Joanna Jedrzejzak; Rhys H Thomas; Javier Salas-Puig; Arnaud Biraben; Bettina Schmitz
Journal:  J Neurol       Date:  2020-04-01       Impact factor: 4.849

9.  Uncertainties from a worldwide survey on antiepileptic drug withdrawal after seizure remission.

Authors:  Luca Bartolini; Shahram Majidi; Mohamad Z Koubeissi
Journal:  Neurol Clin Pract       Date:  2018-04

10.  EEG correlates of seizure freedom in genetic generalized epilepsies.

Authors:  Udaya Seneviratne; Ray C Boston; Mark Cook; Wendyl D'Souza
Journal:  Neurol Clin Pract       Date:  2017-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.